Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Johnson

Showing results (191-200 of 244) with videos related to

Pageof 25
Sort By:
Blood Advances|December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Journal of Medical Genetics|September 24, 2018
Genome sequencing reveals a deep intronic splicing <i>ACVRL1</i> mutation hotspot in Hereditary Haemorrhagic TelangiectasiaWhitney L Wooderchak-Donahue, Jamie McDonald, Andrew Farrell, et al.
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Haematologica|April 11, 2020
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphomaShamzah Araf, Koorosh Korfi, Findlay Bewicke-Copley, et al.
British Journal of Haematology|July 11, 2006
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation studyJennifer M Bird, Rhian Fuge, Bhawna Sirohi, et al.
Blood|January 31, 2013
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMTEsa Jantunen, Ariane Boumendil, Herve Finel, et al.
Blood Cancer Journal|October 16, 2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trialsSimonetta Viviani, Chiara Pavoni, Sally F Barrington, et al.
European Journal of Human Genetics : EJHG|June 13, 2018
Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformationWhitney L Wooderchak-Donahue, Peter Johnson, Jamie McDonald, et al.
Pageof 25

Showing results (191-200 of 244) with videos related to

Sort By:
Pageof 25
Blood Advances|December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Journal of Medical Genetics|September 24, 2018
Genome sequencing reveals a deep intronic splicing <i>ACVRL1</i> mutation hotspot in Hereditary Haemorrhagic TelangiectasiaWhitney L Wooderchak-Donahue, Jamie McDonald, Andrew Farrell, et al.
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Haematologica|April 11, 2020
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphomaShamzah Araf, Koorosh Korfi, Findlay Bewicke-Copley, et al.
British Journal of Haematology|July 11, 2006
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation studyJennifer M Bird, Rhian Fuge, Bhawna Sirohi, et al.
Blood|January 31, 2013
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMTEsa Jantunen, Ariane Boumendil, Herve Finel, et al.
Blood Cancer Journal|October 16, 2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trialsSimonetta Viviani, Chiara Pavoni, Sally F Barrington, et al.
European Journal of Human Genetics : EJHG|June 13, 2018
Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformationWhitney L Wooderchak-Donahue, Peter Johnson, Jamie McDonald, et al.
Pageof 25